Showing results (341-350 of 355) with videos related to

Sort By:
Pageof 36
Blood|April 8, 2025
Acalabrutinib-Obinutuzumab Improves Survival vs Chemoimmunotherapy in treatment-naive CLL in the 6-year Follow-up of ELEVATE-TNJeff P Sharman, Miklos Egyed, Wojciech Jurczak, et al.
Human Molecular Genetics|May 9, 2022
Tracing genetic connections of ancient Hungarians to the 6th-14th century populations of the Volga-Ural regionBea Szeifert, Dániel Gerber, Veronika Csáky, et al.
The Journal of Molecular Diagnostics : JMD|April 23, 2023
Next-Generation Sequencing-Based Genomic Profiling of Children with Acute Myeloid LeukemiaSzilvia Krizsán, Borbála Péterffy, Bálint Egyed, et al.
The Lancet. Haematology|July 30, 2023
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 studyAaron T Gerds, Srdan Verstovsek, Alessandro M Vannucchi, et al.
British Journal of Cancer|June 20, 2023
PersonALL: a genetic scoring guide for personalized risk assessment in pediatric B-cell precursor acute lymphoblastic leukemiaGábor Bedics, Bálint Egyed, Lili Kotmayer, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 8, 2021
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma SubtypesRene-Olivier Casasnovas, George Follows, Josee M Zijlstra, et al.
British Journal of Haematology|May 21, 2021
Screening and monitoring of the BTK<sup>C481S</sup> mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapyCsaba Bödör, Lili Kotmayer, Tamás László, et al.
Journal of Hematology & Oncology|July 17, 2021
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL studyMarie Maerevoet, Josee M Zijlstra, George Follows, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 26, 2022
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL StudyMichael Schuster, Josée Zijlstra, Rene-Olivier Casasnovas, et al.
Future Oncology (London, England)|February 2, 2021
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphomaJatin Shah, Sharon Shacham, Michael Kauffman, et al.
Pageof 36